PAPADOPOULOS STELIOS (CIK 1202098) reported 11 SEC Form 4 insider transactions across 3 companies over the past 18 months (most recent 2026-05-29). Recent activity: Buy EXEL (8,367 shares), Buy OVID (17,578 shares), Sell EXEL (100,000 shares), Sell RGLS (976,253 shares), Sell RGLS (64,635 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-29 | EXELIXIS, INC. (EXEL) | Director | Buy | 8,367 | $0 |
| 2026-04-09 | Ovid Therapeutics Inc. (OVID) | Director | Buy | 17,578 | $45,000 |
| 2025-11-13 | EXELIXIS, INC. (EXEL) | Director | Sell | 100,000 | $4.4M |
| 2025-06-27 | Regulus Therapeutics Inc. (RGLS) | Director | Sell | 976,253 | $0 |
| 2025-06-27 | Regulus Therapeutics Inc. (RGLS) | Director | Sell | 64,635 | $0 |
| 2025-05-30 | EXELIXIS, INC. (EXEL) | Director | Buy | 9,812 | $0 |
| 2025-05-16 | EXELIXIS, INC. (EXEL) | Director | Buy | 20,634 | $407,934 |
| 2025-05-16 | EXELIXIS, INC. (EXEL) | Director | Sell | 20,634 | $915,118 |
| 2025-05-16 | EXELIXIS, INC. (EXEL) | Director | Buy | 15,874 | $325,417 |
| 2025-05-16 | EXELIXIS, INC. (EXEL) | Director | Sell | 15,874 | $704,012 |
| 2025-04-30 | Regulus Therapeutics Inc. (RGLS) | Director | Buy | 62,500 | $0 |
Source: SEC Form 4 filings · as of 2026-05-29